Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intellectual Property

Set Alert for Intellectual Property

US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets

A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.

Intellectual Property Lobbying

Dr Reddy’s Gets $72m Payout From Suboxone Settlement

Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.

Legal Issues Intellectual Property

HEC Pharm Wins Key Reversal In US Gilenya Dosing Patent Fight

China’s HEC Pharm, the last ANDA filer for fingolimod standing in patent litigation, has won a key invalidity challenge against a dosing-regimen patent shielding the multiple sclerosis treatment. However, the Federal Circuit was split on whether it had applied a heightened standard for negative claim limitations.

Intellectual Property Legal Issues

Aurobindo Matches Lupin With Teva Austedo Settlement

Aurobindo has settled US patent litigation with Teva over Austedo, giving the Indian company an April 2033 launch date for generic deutetrabenazine, matching the date gained by Lupin in an earlier settlement.

Intellectual Property Legal Issues

Chugai’s Eldecalcitol Challenge Fails In Japan

Chugai has seen its attack on Sawai and Nichi-Iko over their generic eldecalcitol rivals to the originator’s Edirol brand dismissed by a Tokyo district court.

Legal Issues Intellectual Property

Alimta ANDA Products Hit Double Digits With Several Launches

Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.

Generic Drugs Launches

Senators Slam FDA And PTO For Patent ‘Oversight Gaps’

A “lack of co-ordination” between the US FDA and PTO has allowed patent thickets to grow via the granting of flawed patents that do not meet legal requirements, senators Maggie Hassan and Bill Cassidy have complained.

Intellectual Property United States

Teva Introduces First Eliquis Rival In UK

Teva has capitalized on a recent legal victory in the UK by claiming the first launch of a generic apixaban rival to BMS’ Eliquis.

Launches United Kingdom

Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch

One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.

Legal Issues Intellectual Property
See All